

Studies on phyto chemical screening and wound healing activity of *Eriolaena hookeriana* Wt. & Arn. roots in rats

K.Gnananath¹ and K. Kishore Kumar²

¹Netaji Institute of pharmaceutical sciences, India

²Malla Reddy College of Pharmacy, India

In folklore the roots of this plant were used in treating wounds hence the main aim was to evaluate the wound healing potential of *Eriolaena hookeriana* Wt. & Arn. Wound healing activity was studied in two types of model in rat's viz. excision and incision. In case of the excision wound model parameters like wound contraction and period of epithelization was studied while in incision wound model, tensile strength of the wound was measured. In both the models treatment of wound with ointment containing 5% (w/w) extracts showed good wound healing activity ($p < 0.01$) in comparison with control. The results of present study suggest that extracts of *Eriolaena hookeriana* Wt. & Arn. Possess potent wound healing activity justifying its use in folklore.

k.gnananath@gmail.com

"Pharmerging markets" China, India & Russia - dominating global pharmaceutical markets

G Sudheer Kumar

JSS University, India

The scenario of the global market for pharmaceuticals is undergoing a rapid change. Pharmaceutical emerging markets coined as "pharmerging" by IMS health services include seven developing countries in which China, Russia, India & Brazil are dominating the global pharma market. With established markets becoming saturated, multinational corporations (MNCs) have turned increasingly to emerging markets (EMs) in the developing world. The global pharmaceutical market experienced exponential growth over the past decade but is now witnessing a slump. This slump is attributed to saturation in key markets such as United States and Western Europe, patent expiry of key drug formulations and a static economy. The emerging markets undoubtedly offer high potential, with rising GDPs, expanding access to healthcare and an improving IP and regulatory environment in many cases. As per IMS survey, annual global spending on medicines will reach nearly \$ 2.1 trillion by 2016 as pharmerging markets contribute more spending. Nevertheless, these markets are fraught with uncertainty and hurdles. Local companies are strong and entrenched, domestic products well-established, and generics dominate the market in a growing number of countries. Patent expiries will reduce brand spending by \$127 billion through 2016 due to which the developed markets are expected to grow slowly. Among these pharmerging markets China, India & Russia contribute majority of the growth, it's worth considering investing in these countries rather than investing in saturated markets of developed nations.